Log in
Enquire now
‌

US Patent 11547756 Method of treating influenza A

Patent 11547756 was granted and assigned to MedImmune on January, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

TimelineTable: Further ResourcesReferences
Is a
Patent
Patent
1

Patent attributes

Patent Applicant
MedImmune
MedImmune
1
Current Assignee
MedImmune
MedImmune
1
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
1
Patent Number
115477561
Patent Inventor Names
Song Ren1
Gabriel Robbie1
Nicole Kallewaard-Lelay1
Raburn Mallory1
Date of Patent
January 10, 2023
1
Patent Application Number
169848271
Date Filed
August 4, 2020
1
Patent Citations
‌
US Patent 10494419 Neutralizing anti-influenza A antibodies and uses thereof
‌
US Patent 10442854 Neutralizing anti-influenza binding molecules and uses thereof
‌
US Patent 10519221 Neutralizing anti-influenza B antibodies and uses thereof
1
Patent Primary Examiner
‌
Benjamin P Blumel
1

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11547756 Method of treating influenza A

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.